86
Participants
Start Date
June 30, 2007
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2017
Cisplatin
Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
carboplatin
Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
University of Alabama-Birmingham, Birmingham
UCSF, San Francisco
Georgetown - Lombardi Cancer Center, Washington D.C.
Johns Hopkins University Medical Center, Baltimore
Memorial Sloan Kettering Cancer Center, New York
University of North Carolina, Chapel Hill
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
North Shore Medical Center, Peabody
Beth Israel Deaconess Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER
North Shore Medical Center
OTHER
Massachusetts General Hospital
OTHER